“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.In an interview with Pharmacy Times, Kelly Gaertner, PharmD, an oncology clinical pharmacy specialist with Allegheny Health Network, said that a slew of new treat...
The introduction of trastuzumab (Herceptin) more than 20 years ago transformed survival expectations for patients with HER2-positive breast cancer, especially for those with early-stage disease.1 HER2-positive breast cancer is aggressive, however, and the prognosis for patients with advanced disease at...
“Trastuzumab deruxtecan offers an important new option for patients with HER2 positive metastatic breast cancer in the UK who are in need of new treatment options after their cancer has progressed beyond both first- and second-line therapy,” said Haran Maheson, Commercial Director for...
Pertuzumab: New Drug for HER2-positive Metastatic Breast CancerMatthew Stenger
Resistance to HER2-targeted therapies can be a problem when treating patients with HER2-positive (HER2+) breast cancer. Therefore, the identification of new therapies for this patient group is important. Researchers at the Leibniz Research Center for Working Environments and Human Factors in Dortmund...
HER2-positive breast cancer is highly proliferative, difficult to tre... SR Morris,LA Carey - 《Oncology》 被引量: 0发表: 2007年 Her2-positive breast cancer: Herceptin and beyond As a result, significant efforts have been applied to finding other therapies besides trastuzumab for the treatment ...
Next, O’Shaughnessy reviewed recent developments in the treatment of HER2-positive breast cancer. Tucatinib very selectively inhibits HER2, she said, allowing it to get great brain penetration. The randomized HER2CLIMB trial saw not only improvements in progression-free survival (PFS), but also...
AIM: To compare results of trastuzumab-emtansine (T-DM1) treatment in our clinical practice with data from phase III clinical trials. PATIENTS AND METHODS: A retrospective chart review of all 23 patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who wer...
"Mitochondrial creatine kinase 1 may be a new drug target for the treatment of HER2 positive breast cancer," says Matthew Goetz, M.D., director of the Mayo Clinic Breast Cancer research program. "Future clinical trials will be necessary to determine the effectiveness of thisdrugfor HER2 positiv...